MariaDB Accelerates Cloud Deployments, Adds Agentic AI and Serverless Capability with Acquisition of SkySQL
26.8.2025 15:00:00 CEST | Business Wire | Press Release
MariaDB plc today announced it has acquired SkySQL Inc., the company behind an AI-powered, serverless database-as-a-service (DBaaS) platform. The acquisition brings SkySQL’s established DBaaS product back into the MariaDB portfolio. SkySQL was originally developed by MariaDB and, since being spun off as an independent entity in 2023, has significantly advanced its product offering. The acquisition of SkySQL enables MariaDB to meet customer and market expectations for greater flexibility and deployment choice, including a range of self-managed and fully managed cloud offerings. MariaDB Cloud will encompass the SkySQL capability and form a key part of the product portfolio.
“Our customers have made it clear that they want flexibility, and they need powerful, reliable database solutions wherever their business takes them – on premises, in the cloud or in hybrid environments,” said Rohit de Souza, CEO, MariaDB plc. “Acquiring SkySQL helps accelerate plans and adds further innovation to MariaDB Cloud. It’s a strategic investment in our customers and a decisive step to enhance our ability to provide the comprehensive, modern, world-class database platform our customers need to thrive and maintain a competitive edge.”
According to an IDC market forecast, enterprises are increasingly shifting workloads to cloud-based database solutions to achieve greater scalability, cost efficiency and accessibility. This migration is motivated by the need for a flexible infrastructure that can adapt to changing business requirements and support distributed teams (IDC Tech Supplier, “Worldwide Database Management Systems Software Forecast,” 2025-2029, US53032525, June 2025). MariaDB Cloud provides a provisioned database, as a service, on all three major public clouds (AWS, Azure, Google Cloud), along with a serverless mode for developers to instantly start building cloud-native and AI-driven applications without overspending. Further, integrated agentic AI capabilities help transform how developers interact with complex operational data. MariaDB Cloud will enable customers to consume MariaDB Enterprise Platform, the company’s flagship product, as a fully managed cloud option. MariaDB Enterprise Platform delivers best-in-class performance, data security, replication, clustering and high availability for production workloads.
“SkySQL’s level of sophistication, from its built-in elasticity, advanced serverless technology, to its agentic AI capabilities, is extremely impressive,” said Vikas Mathur, chief product officer, MariaDB plc. “By bringing SkySQL’s DBaaS into the MariaDB portfolio, we are immediately addressing our customers’ needs while also gaining a robust foundation to make MariaDB the default option for building GenAI applications.”
With the acquisition, the entire SkySQL team joins and integrates into MariaDB, further bolstering MariaDB’s product, engineering, support and go-to-market teams with additional DBaaS expertise.
“I am incredibly proud of what we’ve been able to build with SkySQL in a short period of time, a database service that scales effortlessly with serverless workloads and enables reliable, AI-driven applications,” said Jags Ramnarayan, chief technology officer, SkySQL Inc. “This acquisition is a major win for our customers who will now benefit from our joint efforts and faster innovation cycles. As a part of MariaDB again, we are now able to bring this capability to customers across the globe faster and more effectively.”
The acquisition of SkySQL comes on the heels of another recent acquisition of a high availability solution, Galera Cluster in June 2025 and launch of a new and improved version of MariaDB Enterprise Platform in January 2025, which included the introduction of open source vector search. MariaDB Enterprise Platform was recently recognized as Best Overall Database in the 2025 DBTA Readers’ Choice Award and Best in Open Source AI in the 2025 AI TechAwards. MariaDB’s momentum this year follows the take-private transaction by K1 Investment Management and appointment of Rohit de Souza as MariaDB’s CEO in September 2024.
Get started with MariaDB Cloud today at: mariadb.com/cloud-get-started/.
Additional Resources
- Learn about MariaDB Cloud
- Get started with MariaDB Cloud (MariaDB SkySQL) today
- Follow @mariadb on X and LinkedIn
- Read MariaDB’s blog
About MariaDB
MariaDB seeks to eliminate the constraints and complexity of proprietary databases, enabling organizations to reinvest in what matters most – rapidly developing innovative, customer-facing applications. Enterprises can depend on a single complete database for all their needs, that can be deployed in minutes for transactional, analytical and hybrid use cases. Trusted by organizations such as Deutsche Bank, DBS Bank, Red Hat, ServiceNow and Samsung – MariaDB delivers customer value without the financial burden of legacy database providers. For more information, please visit mariadb.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250826903551/en/
Contacts
pr@mariadb.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom